Literature DB >> 2532156

Potent selective inhibitors of protein kinase C.

P D Davis1, C H Hill, E Keech, G Lawton, J S Nixon, A D Sedgwick, J Wadsworth, D Westmacott, S E Wilkinson.   

Abstract

A series of potent, selective inhibitors of protein kinase C has been derived from the structural lead provided by the microbial broth products, staurosporine and K252a. Our inhibitors block PCK in intact cells (platelets and T cells), and prevent the proliferation of mononuclear cells in response to interleukin 2 (IL2).

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2532156     DOI： 10.1016/0014-5793(89)81494-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  113 in total

1.  Staurosporine, but not Ro 31-8220, induces interleukin 2 production and synergizes with interleukin 1alpha in EL4 thymoma cells.

Authors:  T M Mahon; J S Matthews; L A O'Neill
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein.

Authors:  V Duronio; M J Welham; S Abraham; P Dryden; J W Schrader
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

3.  Selective activation of p42 mitogen-activated protein (MAP) kinase in murine B lymphoma cell lines by membrane immunoglobulin cross-linking. Evidence for protein kinase C-independent and -dependent mechanisms of activation.

Authors:  M R Gold; J S Sanghera; J Stewart; S L Pelech
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

4.  Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor.

Authors:  M J Mulqueen; D Bradshaw; P D Davis; L Elliott; T A Griffiths; C H Hill; H Kumar; G Lawton; J S Nixon; A D Sedgwick
Journal:  Agents Actions       Date:  1992-09

5.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

6.  Inhibition of glucose-stimulated insulin secretion by Ro 31-8220, a protein kinase C inhibitor.

Authors:  S J Persaud; P M Jones
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

7.  A role for protein kinase C subtypes alpha and epsilon in phorbol-ester-enhanced K(+)- and carbachol-evoked noradrenaline release from the human neuroblastoma SH-SY5Y.

Authors:  N A Turner; M G Rumsby; J H Walker; F A McMorris; S G Ball; P F Vaughan
Journal:  Biochem J       Date:  1994-01-15       Impact factor: 3.857

8.  Inhibition by glucocorticoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40.

Authors:  A Katira; K A Knox; M Finney; R H Michell; M Wakelam; J Gordon
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Mechanical and biochemical responses to endothelin-1 and endothelin-3 in bovine bronchial smooth muscle.

Authors:  J E Nally; R McCall; L C Young; M J Wakelam; N C Thomson; J C McGrath
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

10.  Pharmacological comparison of LTB(4)-induced NADPH oxidase activation in adherent and non-adherent guinea-pig eosinophils.

Authors:  O T Lynch; M A Giembycz; P J Barnes; M A Lindsay
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.